Broadcom Inc. (AVGO) vs Regeneron Pharmaceuticals, Inc. (REGN): Which Is the Better Buy in 2026?
As of 2026-06-19, AVGO is overvalued at $411, with a DCF intrinsic value of $258 and a margin of safety of -59%. REGN is undervalued at $610, with an intrinsic value of $1572 and a margin of safety of 61%. Of the two, REGN has the wider margin of safety.
Rewards
- ★Gross margin of 76.3% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
- ★Free cash flow has grown at a 18.2% CAGR over the past 4 years, demonstrating strong earnings power growth.
- ★Each dollar of retained earnings has created $11.66 of earning power — management is an exceptional capital allocator.
- ★Regeneron Pharmaceuticals, Inc. scores 80/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
- ★Trailing P/E of 14.9x is 22% below the historical average of 19.2x — potentially undervalued relative to its own history.
- ★Altman Z-Score of 7.56 indicates very low bankruptcy risk — the company is firmly in the safe zone.
Risks
- ⚠ROIC has declined by 6.5 percentage points over the past 4 years, which may signal competitive erosion.
- ⚠Share count has increased by 13% over the past 4 years, diluting existing shareholders.
- ⚠FCF yield of 1.4% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
- ⚠ROIC has declined by 7.3 percentage points over the past 4 years, which may signal competitive erosion.
- ⚠Each dollar of retained earnings has produced only $0.15 of earning power — shareholders may have been better served by dividends.
- ⚠FCF yield of 5.1% suggests reasonable valuation assuming continued moderate growth.
Key Valuation Metrics
Learn more →Historical Fundamentals
Learn more →Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.
Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.
Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.
$1 Retained Earnings Test
Learn more →> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
Discounted Cash Flow (DCF) Analysis
Learn more →Reverse DCF — Market-Implied Growth
Learn more →What growth rate is the market pricing in at $411?
The market implies +23.6% Owner Earnings growth, above historical trends.
Standard FCF implies a demanding +25.6%, reflecting heavy growth investment.
What growth rate is the market pricing in at $610?
The market implies +1.6% Owner Earnings growth, roughly in line with history — reasonably priced.
Standard FCF implies +6.0%, reflecting ongoing growth investment.
Economic Moat Score
Learn more →Narrow moat with reinvestment efficiency as the key competitive advantage. Improving revenue predictability would strengthen the moat.
Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.
Forensic Accounting
Learn more →M-Score Trend
M-Score Trend
Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
Ownership Breakdown
Learn more →High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.
Insider Buying Activity
Learn more →Open market purchases · includes direct & indirect ownership · excludes option exercises.
Insider Selling Activity
Learn more →Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.
🎭 Mr. Market's Mood
Learn more →"Market is pricing this stock without strong emotion in either direction"
"Market is pricing this stock without strong emotion in either direction"
Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
⚖️ Buffett Signal
Learn more →The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.
The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.
Frequently Asked Questions: AVGO vs REGN
Is Broadcom Inc. or Regeneron Pharmaceuticals, Inc. more undervalued in 2026?▼
Based on our discounted cash flow model, REGN trades at a 61.2% margin of safety (intrinsic value $1572 vs. price $610), compared to AVGO's -59.4% margin of safety (intrinsic $258 vs. $411).
Which stock has a wider economic moat, Broadcom Inc. or Regeneron Pharmaceuticals, Inc.?▼
REGN scores 80/100 (Wide moat), while AVGO scores 61/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.
Which company has better free cash flow, Broadcom Inc. or Regeneron Pharmaceuticals, Inc.?▼
Regeneron Pharmaceuticals, Inc. (REGN) generates a 5.1% free cash flow yield, compared to Broadcom Inc.'s 1.4%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.
Which stock has higher return on invested capital, Broadcom Inc. or Regeneron Pharmaceuticals, Inc.?▼
AVGO earns 19.1% ROIC versus REGN's 7.1%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.
Which dividend is safer, Broadcom Inc.'s or Regeneron Pharmaceuticals, Inc.'s?▼
AVGO's dividend earns a safety score of 94/100 (Very Safe), compared to REGN's 85/100 (Very Safe). AVGO has raised its dividend for 3 consecutive years.